Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Amiloride-H for central serous chorioretinopathy
IRCT20190311043009N1Phase 3Completed
- Sponsor
- Isfahan University of Medical Sciences
- Start
- Apr 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of amiloride in Central Serous Chorioretinopathy (CSCR) (2 arms), sponsored by Isfahan University of Medical Sciences. Primary endpoints: Best corrected visual acuity, Central thickness of macula and 1 more. Started Apr 2019; status: completed.
02
Drugs
amiloride
03
Conditions
Central Serous Chorioretinopathy (CSCR)
Beyond the preview
Go deeper on IRCT20190311043009N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20190311043009N1.